Improving the surgical experience in gynecologic oncology patients with use of patient engagement technology: A prospective cohort study

2020 ◽  
Vol 159 ◽  
pp. 296
Author(s):  
H.J. Smith ◽  
J.M. Straughn ◽  
M.I. Liang ◽  
C.A. Leath ◽  
D.I. Chu
Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 12
Author(s):  
Innocenza Palaia ◽  
Giuseppe Caruso ◽  
Violante Di Donato ◽  
Annarita Vestri ◽  
Anna Napoli ◽  
...  

Objective: To evaluate the safety and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in gynecologic oncology patients under chemotherapy. Methods: A prospective cohort study including gynecologic oncology women who were under chemotherapy or had completed it within 6 months at the time of the study. All patients received a two-dose schedule of the Pfizer-BioNTech COVID-19 vaccine. Results were compared with a control group of healthy women vaccinated in the same period. Results: Overall, 44 oncologic patients with a mean age of 61.3 ± 10.7 years were enrolled: 28 (63.6%) had ovarian cancer, 9 (20.4%) endometrial, and 7 (16%) cervical. The IgG antibody titer after 1 month from vaccination was low in 9 (20.5%) patients, moderate in 21 (47.7%), and high in 14 (31.8%). The 3-month titer was null in 2 (4.5%) patients, low in 26 (59.1%), moderate in 13 (29.5%), and high in 3 (6.8%). Patients ≥ 50 years reported lower 1-month (p = 0.018) and 3-month (p = 0.004) titers compared with <50 years. Patients with BMI < 30 kg/m2 had a higher 1-month titer compared with BMI ≥ 30 kg/m2 (p = 0.016). Compared with healthy women (n = 44), oncologic patients showed a lower 3-month titer (p < 0.001). None of the patients experienced serious adverse effects. Conclusions: The COVID-19 vaccine was safe and immunogenic in gynecologic oncology patients under chemotherapy. Serological monitoring and further vaccine shots should be considered to boost protection.


2020 ◽  
Vol 122 (6) ◽  
pp. 1027-1030 ◽  
Author(s):  
Jonathan D. Stevenson ◽  
Scott Evans ◽  
Guy Morris ◽  
Roger Tillman ◽  
Adesegun Abudu ◽  
...  

2018 ◽  
Vol 7 (5) ◽  
pp. e136 ◽  
Author(s):  
Michael Marthick ◽  
Haryana M Dhillon ◽  
Jennifer A Alison ◽  
Birinder S Cheema ◽  
Tim Shaw

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Fuqing Zhang ◽  
Mengxia Yao ◽  
Zhiping Lin ◽  
Yili Chen ◽  
Hui Jiang ◽  
...  

Background. Immune dysfunction can occur after neoadjuvant chemotherapy (NAC) and surgery for cancer. We investigated whether preoperative oral carbohydrate affected the postoperative percentages of T cells (CD4+ and CD8+) and natural killer (NK) cells in patients with cervical cancer treated with NAC and surgery. Methods. This prospective cohort study enrolled consecutive patients with cervical cancer treated by radical hysterectomy with PLND at the Gynecologic Oncology Department of Fujian Provincial Cancer Hospital (China) between January 2018 and December 2018. Patients were divided into three groups according to the treatment method: NAC (two cycles, surgery 1 month later), NAC+CHO (chemotherapy and surgical methods same as with the NAC group but with 300 mL of oral carbohydrate administered 2 h before surgery), and non-NAC (surgery alone). Percentages of NK, CD3+, CD4+, and CD8+ cells were evaluated by flow cytometry the day after the first admission, just before surgery, immediately after tracheal tube removal, and the day after surgery. This trial is registered with NCT03872635 at clinicaltrials.com. Results. The final analysis included 77 patients (non-NAC group, n=26; NAC group, n=25; and NAC-CHO group, n=26). Baseline characteristics and preoperative NK, CD3+, CD4+, and CD8+ cell percentages were similar between groups. Postoperatively, all groups exhibited reductions in NK, CD3+, and CD4+ cell percentages and increases in CD8+ cell percentages (all P<0.05). The changes in NK, CD3+, CD4+, and CD8+ cell percentages were attenuated in the NAC-CHO group (P<0.05 vs. both other groups). Conclusion. Preoperative oral carbohydrate can improve the postoperative populations of NK and T cells after the treatment of cervical cancer by NAC and surgery.


Sign in / Sign up

Export Citation Format

Share Document